You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • SAT0134 Biologic free disease control (BFDC) in early RA: Predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ada plus methotrexate (MTX) – data from the optima study

Article info

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Posters
Rheumatoid arthritis – anti-TNF therapy
SAT0134 Biologic free disease control (BFDC) in early RA: Predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ada plus methotrexate (MTX) – data from the optima study

Authors

Citation

Smolen J, Emery P, Fleischmann R, et al
SAT0134 Biologic free disease control (BFDC) in early RA: Predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activity with ada plus methotrexate (MTX) – data from the optima study
Annals of the Rheumatic Diseases 2013;71:516.

Publication history

  • First published January 23, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions